This two-phase study aims to explore ways to predict who will respond well to the weight loss
drug lorcaserin and to understand the mechanisms that develop which limit drug efficacy.
Subjects will be recruited for a 5-week crossover study (phase 1) with lorcaserin and placebo
followed by treatment with lorcaserin for 24 weeks (phase 2).
Phase:
Phase 4
Details
Lead Sponsor:
Columbia University
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) New York State Psychiatric Institute